BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Rovers KP, Simkens GA, Punt CJ, van Dieren S, Tanis PJ, de Hingh IH. Perioperative systemic therapy for resectable colorectal peritoneal metastases: Sufficient evidence for its widespread use? A critical systematic review. Crit Rev Oncol Hematol 2017;114:53-62. [PMID: 28477747 DOI: 10.1016/j.critrevonc.2017.03.028] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 5.2] [Reference Citation Analysis]
Number Citing Articles
1 Witmer HDD, Dhiman A, Turaga KK. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastases: Where do we stand? Cancer 2023;129:495-502. [PMID: 36527271 DOI: 10.1002/cncr.34567] [Reference Citation Analysis]
2 Cashin PH, Esquivel J, Larsen SG, Liauw W, Alzahrani NA, Morris DL, Kepenekian V, Sourrouille I, Dumont F, Tuech J, Ceribelli C, Doussot B, Sgarbura O, Quenet F, Glehen O, Fisher OM. Perioperative chemotherapy in colorectal cancer with peritoneal metastases: A global propensity score matched study. eClinicalMedicine 2023;55:101746. [DOI: 10.1016/j.eclinm.2022.101746] [Reference Citation Analysis]
3 Tonello M, Baratti D, Sammartino P, Di Giorgio A, Robella M, Sassaroli C, Framarini M, Valle M, Macrì A, Graziosi L, Fugazzola P, Lippolis PV, Gelmini R, Biacchi D, Kasamura S, Deraco M, Cenzi C, Del Bianco P, Vaira M, Sommariva A. External validation of COMPASS and BIOSCOPE prognostic scores in colorectal peritoneal metastases treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC). European Journal of Surgical Oncology 2022. [DOI: 10.1016/j.ejso.2022.10.007] [Reference Citation Analysis]
4 Weksler Y, Hoffman A, Green E, Kyzer M, Nevo N, Gerstenhaber F, Greenberg R, Klausner JM, Gutman M, Lahat G, Berger Y, Geva R, Nizri E. Long-term outcomes of elderly patients with peritoneal metastases of colorectal origin after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Surg Oncol 2022;44:101848. [PMID: 36126349 DOI: 10.1016/j.suronc.2022.101848] [Reference Citation Analysis]
5 Flood MP, Kong JCH, Wilson K, Mohan H, Waters PS, Mccormick JJ, Warrier SK, Tie J, Ramsay R, Michael M, Heriot AG. The Impact of Neoadjuvant Chemotherapy on the Surgical Management of Colorectal Peritoneal Metastases: A Systematic Review and Meta-Analysis. Ann Surg Oncol. [DOI: 10.1245/s10434-022-11699-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
6 Kim YJ, Kim CH. Treatment for Peritoneal Metastasis of Patients With Colorectal Cancer. Ann Coloproctol 2021;37:425-33. [PMID: 34961304 DOI: 10.3393/ac.2021.00920.0131] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
7 Tonello M, Baratti D, Sammartino P, Di Giorgio A, Robella M, Sassaroli C, Framarini M, Valle M, Macrì A, Graziosi L, Coccolini F, Lippolis PV, Roberta G, Deraco M, Biacchi D, Santullo F, Vaira M, Di Lauro K, D'Acapito F, Carboni F, Giuffrè G, Donini A, Fugazzola P, Faviana P, Lorena S, Scapinello A, Del Bianco P, Sommariva A. Microsatellite and RAS/RAF Mutational Status as Prognostic Factors in Colorectal Peritoneal Metastases Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC). Ann Surg Oncol 2021. [PMID: 34783946 DOI: 10.1245/s10434-021-11045-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
8 Nizri E, Berger Y, Green E, Kyzer M, Aizic A, Nevo N, Gerstenhaber F, Klausner JM, Gutman M, Lahat G, Hoffman A, Geva R. Lymph Node Metastases from Visceral Peritoneal Colorectal Metastases are Associated with Systemic Recurrence. Ann Surg Oncol 2021. [PMID: 34622371 DOI: 10.1245/s10434-021-10869-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
9 Ceelen W, Demuytere J, de Hingh I. Hyperthermic Intraperitoneal Chemotherapy: A Critical Review. Cancers (Basel) 2021;13:3114. [PMID: 34206563 DOI: 10.3390/cancers13133114] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
10 Ljunggren M, Nordenvall C, Palmer G. Direct surgery with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for patients with colorectal peritoneal metastases. Eur J Surg Oncol 2021:S0748-7983(21)00541-2. [PMID: 34116900 DOI: 10.1016/j.ejso.2021.05.046] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
11 Rovers KP, Bakkers C, Nienhuijs SW, Burger JWA, Creemers GM, Thijs AMJ, Brandt-Kerkhof ARM, Madsen EVE, van Meerten E, Tuynman JB, Kusters M, Versteeg KS, Aalbers AGJ, Kok NFM, Buffart TE, Wiezer MJ, Boerma D, Los M, de Reuver PR, Bremers AJA, Verheul HMW, Kruijff S, de Groot DJA, Witkamp AJ, van Grevenstein WMU, Koopman M, Nederend J, Lahaye MJ, Kranenburg O, Fijneman RJA, van 't Erve I, Snaebjornsson P, Hemmer PHJ, Dijkgraaf MGW, Punt CJA, Tanis PJ, de Hingh IHJT; Dutch Peritoneal Oncology Group and the Dutch Colorectal Cancer Group. Perioperative Systemic Therapy vs Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Alone for Resectable Colorectal Peritoneal Metastases: A Phase 2 Randomized Clinical Trial. JAMA Surg 2021;156:710-20. [PMID: 34009291 DOI: 10.1001/jamasurg.2021.1642] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
12 van de Vlasakker VCJ, Lurvink RJ, Cashin PH, Ceelen W, Deraco M, Goéré D, González-Moreno S, Lehmann K, Li Y, Moran B, Morris DL, Piso P, Quadros CA, Rau B, Somashekhar SP, Sommariva A, van der Speeten K, Spiliotis J, Sugarbaker PH, Teo MCC, Verwaal VJ, Yonemura Y, Glehen O, de Hingh IHJT. The impact of PRODIGE 7 on the current worldwide practice of CRS-HIPEC for colorectal peritoneal metastases: A web-based survey and 2021 statement by Peritoneal Surface Oncology Group International (PSOGI). Eur J Surg Oncol 2021:S0748-7983(21)00499-6. [PMID: 34020808 DOI: 10.1016/j.ejso.2021.05.023] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
13 Rovers KP, Kok NFM, Punt CJA, Tanis PJ, de Hingh IHJT. Limitations of the PRODIGE 7 trial. Lancet Oncol 2021;22:e174. [PMID: 33932372 DOI: 10.1016/S1470-2045(21)00063-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
14 Bakkers C, Simkens GAAM, De Hingh IHJT. Systemic therapy in addition to cytoreduction and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastases: recent insights from clinical studies and translational research. J Gastrointest Oncol 2021;12:S206-13. [PMID: 33968438 DOI: 10.21037/jgo-20-133] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
15 Repullo DJ, Barbois S, Leonard D, Bohlok A, Van den Audenaeren ET, Hendlisz A, Van den Eynde M, Donckier V, Kartheuser A, Liberale G. The absence of benefit of perioperative chemotherapy in initially resectable peritoneal metastases of colorectal cancer origin treated with complete cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: A retrospective analysis. Eur J Surg Oncol 2021;47:1661-7. [PMID: 33602530 DOI: 10.1016/j.ejso.2021.01.018] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
16 Gül-klein S, Müller V, Alberto M, Brandl A, Rau B. Die Rolle von zytoreduktiver Chirurgie und HIPEC beim Kolonkarzinom. Chirurgie des Kolonkarzinoms 2021. [DOI: 10.1007/978-3-662-60453-3_32] [Reference Citation Analysis]
17 Bhatt A, Rousset P, Benzerdjeb N, Kammar P, Mehta S, Parikh L, Goswami G, Shaikh S, Kepenekian V, Passot G, Glehen O. Prospective correlation of the radiological, surgical and pathological findings in patients undergoing cytoreductive surgery for colorectal peritoneal metastases: implications for the preoperative estimation of the peritoneal cancer index. Colorectal Dis 2020;22:2123-32. [PMID: 32940414 DOI: 10.1111/codi.15368] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
18 Bhatt A, Képénékian V, Benzerdjeb N, Glehen O. ASO Author Reflections: Potential Therapeutic Implications and Prediction of Pathological Complete Response to Systemic Chemotherapy in Colorectal Peritoneal Metastases. Ann Surg Oncol 2021;28:3850-1. [PMID: 33211229 DOI: 10.1245/s10434-020-09378-6] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
19 Bhatt A, Rousset P, Benzerdjeb N, Kammar P, Mehta S, Parikh L, Goswami G, Shaikh S, Kepenekian V, Passot G, Glehen O. Clinical and Radiologic Predictors of a Pathologic Complete Response to Neoadjuvant Chemotherapy (NACT) in Patients Undergoing Cytoreductive Surgery for Colorectal Peritoneal Metastases: Results of a Prospective Multi-center Study. Ann Surg Oncol 2021;28:3840-9. [PMID: 33210270 DOI: 10.1245/s10434-020-09330-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
20 Tanis PJ, Tuynman JB, de Hingh IHJT. Results from the PROPHYLOCHIP-PRODIGE 15 trial. Lancet Oncol 2020;21:e496. [PMID: 33152288 DOI: 10.1016/S1470-2045(20)30497-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
21 Sommariva A, Ansaloni L, Baiocchi GL, Cascinu S, Cirocchi R, Coccolini F, Deraco M, Fiorentini G, Gelmini R, Di Giorgio A, Lippolis PV, Pasqual EM, Sassaroli C, Macrì A, Sammartino P, Scaringi S, Valle M, Vaira M. Diagnostic and therapeutic algorithm for colorectal peritoneal metastases. A consensus of the peritoneal surface malignancies onco-team of the Italian society of surgical oncology. Eur J Surg Oncol 2021;47:164-71. [PMID: 33028502 DOI: 10.1016/j.ejso.2020.09.035] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
22 Rovers KP, Bakkers C, van Erning FN, Burger JWA, Nienhuijs SW, Simkens GAAM, Creemers GM, Hemmer PHJ, Punt CJA, Lemmens VEPP, Tanis PJ, de Hingh IHJT. Adjuvant Systemic Chemotherapy vs Active Surveillance Following Up-front Resection of Isolated Synchronous Colorectal Peritoneal Metastases. JAMA Oncol 2020;6:e202701. [PMID: 32672798 DOI: 10.1001/jamaoncol.2020.2701] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]
23 Bakkers C, van Erning FN, Rovers KP, Nienhuijs SW, Burger JW, Lemmens VE, Aalbers AG, Kok NF, Boerma D, Brandt AR, Hemmer PH, van Grevenstein WM, de Reuver PR, Tanis PJ, Tuynman JB, de Hingh IH. Long-term survival after hyperthermic intraperitoneal chemotherapy using mitomycin C or oxaliplatin in colorectal cancer patients with synchronous peritoneal metastases: A nationwide comparative study. Eur J Surg Oncol 2020;46:1902-7. [PMID: 32340819 DOI: 10.1016/j.ejso.2020.04.018] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 5.3] [Reference Citation Analysis]
24 Hulshof EC, Lurvink RJ, Caserta N, de Hingh IHJT, van Wezel T, Böhringer S, Swen JJ, Gelderblom H, Guchelaar HJ, Deenen MJ. Identification of pharmacogenetic biomarkers for efficacy of cytoreductive surgery plus hyperthermic intraperitoneal mitomycin C in patients with colorectal peritoneal metastases. Eur J Surg Oncol 2020;46:1925-31. [PMID: 32354538 DOI: 10.1016/j.ejso.2020.04.019] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
25 Woeste MR, Philips P, Egger ME, Scoggins CR, McMasters KM, Martin RCG. Optimal perfusion chemotherapy: A prospective comparison of mitomycin C and oxaliplatin for hyperthermic intraperitoneal chemotherapy in metastatic colon cancer. J Surg Oncol 2020;121:1298-305. [PMID: 32239529 DOI: 10.1002/jso.25920] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
26 Taibi A, Lo Dico R, Kaci R, Naneix AL, Mathonnet M, Pocard M. Impact of preoperative chemotherapy on the histological response of patients with peritoneal metastases from colorectal cancer according to peritoneal regression grading score (PRGS) and TRG. Surg Oncol 2020;33:158-63. [PMID: 32561082 DOI: 10.1016/j.suronc.2020.02.014] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
27 Bhatt A, Glehen O. Colorectal Peritoneal Metastases: Correlating Histopathological Findings and Disease Biology. Pathology of Peritoneal Metastases 2020. [DOI: 10.1007/978-981-15-3773-8_4] [Reference Citation Analysis]
28 Hentzen JEKR, van der Plas WY, Kuipers H, Ramcharan S, Been LB, Hoogwater FJH, van Ginkel RJ, van Dam GM, Hemmer PHJ, Kruijff S. Delta peritoneal cancer index (ΔPCI): A new dynamic prognostic parameter for survival in patients with colorectal peritoneal metastases. Eur J Surg Oncol 2020;46:590-9. [PMID: 31806520 DOI: 10.1016/j.ejso.2019.11.515] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
29 Wisselink DD, Braakhuis LL, Gallo G, van Grevenstein WM, van Dieren S, Kok NF, de Reuver PR, Tanis PJ, de Hingh IH. Systematic review of published literature on oxaliplatin and mitomycin C as chemotherapeutic agents for hyperthermic intraperitoneal chemotherapy in patients with peritoneal metastases from colorectal cancer. Critical Reviews in Oncology/Hematology 2019;142:119-29. [DOI: 10.1016/j.critrevonc.2019.06.014] [Cited by in Crossref: 30] [Cited by in F6Publishing: 34] [Article Influence: 7.5] [Reference Citation Analysis]
30 Rovers KP, Bakkers C, Simkens GAAM, Burger JWA, Nienhuijs SW, Creemers GM, Thijs AMJ, Brandt-Kerkhof ARM, Madsen EVE, Ayez N, de Boer NL, van Meerten E, Tuynman JB, Kusters M, Sluiter NR, Verheul HMW, van der Vliet HJ, Wiezer MJ, Boerma D, Wassenaar ECE, Los M, Hunting CB, Aalbers AGJ, Kok NFM, Kuhlmann KFD, Boot H, Chalabi M, Kruijff S, Been LB, van Ginkel RJ, de Groot DJA, Fehrmann RSN, de Wilt JHW, Bremers AJA, de Reuver PR, Radema SA, Herbschleb KH, van Grevenstein WMU, Witkamp AJ, Koopman M, Haj Mohammad N, van Duyn EB, Mastboom WJB, Mekenkamp LJM, Nederend J, Lahaye MJ, Snaebjornsson P, Verhoef C, van Laarhoven HWM, Zwinderman AH, Bouma JM, Kranenburg O, van 't Erve I, Fijneman RJA, Dijkgraaf MGW, Hemmer PHJ, Punt CJA, Tanis PJ, de Hingh IHJT; Dutch Peritoneal Oncology Group (DPOG)., Dutch Colorectal Cancer Group (DCCG). Perioperative systemic therapy and cytoreductive surgery with HIPEC versus upfront cytoreductive surgery with HIPEC alone for isolated resectable colorectal peritoneal metastases: protocol of a multicentre, open-label, parallel-group, phase II-III, randomised, superiority study (CAIRO6). BMC Cancer 2019;19:390. [PMID: 31023318 DOI: 10.1186/s12885-019-5545-0] [Cited by in Crossref: 53] [Cited by in F6Publishing: 63] [Article Influence: 13.3] [Reference Citation Analysis]
31 Pinto A, Hobeika C, Philis A, Kirzin S, Carrère N, Ghouti L. Synchronous liver metastases and peritoneal carcinomatosis from colorectal cancer: different strategies for curative treatment? Langenbecks Arch Surg 2019;404:477-88. [PMID: 31025165 DOI: 10.1007/s00423-019-01787-w] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
32 Hentzen JEKR, Rovers KP, Kuipers H, van der Plas WY, Been LB, Hoogwater FJH, van Ginkel RJ, Hemmer PHJ, van Dam GM, de Hingh IHJT, Kruijff S. Impact of Synchronous Versus Metachronous Onset of Colorectal Peritoneal Metastases on Survival Outcomes After Cytoreductive Surgery (CRS) with Hyperthermic Intraperitoneal Chemotherapy (HIPEC): A Multicenter, Retrospective, Observational Study. Ann Surg Oncol 2019;26:2210-21. [PMID: 30877495 DOI: 10.1245/s10434-019-07294-y] [Cited by in Crossref: 30] [Cited by in F6Publishing: 33] [Article Influence: 7.5] [Reference Citation Analysis]
33 Follette C, Liebscher S, Mouw T, Al-kasspooles M. Hyperthermic Intraperitoneal Chemotherapy (HIPEC) and Cytoreductive Surgery (CRS) for Colorectal Cancer: Potential for Individualized Care, Review of Current Treatment Trends, Recent Advancements, and a Look into the Future. Curr Colorectal Cancer Rep 2019;15:36-44. [DOI: 10.1007/s11888-019-00427-1] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
34 Bhatt A, Kammar P, Mehta S, Damodaran D, Zaveri S, Patel MD, Sinukumar S, Ray M, Seshadri R. Chasing Rainbows? the Possibility of "Cure" in Patients with Colorectal Peritoneal Metastases Undergoing Cytoreductive Surgery and HIPEC-a Retrospective Study by INDEPSO. Indian J Surg Oncol 2019;10:49-56. [PMID: 30886494 DOI: 10.1007/s13193-019-00879-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
35 Simkens GA, Rovers KP, Nienhuijs SW, de Hingh IH. Patient selection for cytoreductive surgery and HIPEC for the treatment of peritoneal metastases from colorectal cancer. Cancer Manag Res 2017;9:259-66. [PMID: 28721098 DOI: 10.2147/CMAR.S119569] [Cited by in Crossref: 36] [Cited by in F6Publishing: 39] [Article Influence: 6.0] [Reference Citation Analysis]